Sencresus 25/50/100/200 mg FC tablets
PDF Leaflet Revision Date: 24 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Monotherapy and adjunctive therapy for epilepsy.
Dosage (summary)
Adults: Start at 25 mg nightly, target 100 mg/day, max 400 mg. Children: 0.5-1 mg/kg nightly, target 3-6 mg/kg/day.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Teratogenic; contraindicated in pregnancy and lactation.
Key Drug Interactions
- Phenytoin
- Carbamazepine
- Oral contraceptives
Contraindications
- Hypersensitivity
- Children under 2 years
- Pregnancy
- Women of childbearing potential without prevention programme
Common side effects
- Weight loss
- Drowsiness
- Depression
- Dizziness
- Nephrolithiasis
Counselling Points
- Monitor for weight loss
- Stay hydrated to reduce nephrolithiasis risk
- Use effective contraception in women of childbearing potential
Serious warnings
- Acute myopia and secondary angle closure glaucoma
- Metabolic acidosis
- Risk of hyperammonemia
Important Disclaimer
The Sencresus 25/50/100/200 mg FC tablets professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
